Affiliation: University of Auckland
Country: New Zealand
- Invasive group A streptococcal infection and vaccine implications, Auckland, New ZealandAtheer Safar
Auckland City Hospital, Auckland, New Zealand
Emerg Infect Dis 17:983-9. 2011..Seventy-four percent of patients who died had an underlying condition. To the population in our study, the proposed 26-valent vaccine would provide limited benefit...
- Nurse-led school-based clinics for skin infections and rheumatic fever prevention: results from a pilot study in South AucklandSarah Gray
Counties Manukau District Health Board, Auckland, New Zealand
N Z Med J 126:53-61. 2013..To assess the acceptability and feasibility of delivering targeted primary health care in a decile one primary school setting...
- The epidemiology of rheumatic fever in the Tairawhiti/Gisborne region of New Zealand: 1997-2009Victoria Siriett
The University of Auckland, Auckland, Tamaki Campus, School of Population Health, Auckland, 1142, New Zealand
N Z Med J 125:8-15. 2012..To establish Acute Rheumatic Fever (ARF) rates within the Tairawhiti District Health Board (1997-2009) to identify communities for primary prevention programmes...
- Reducing inequalities with vaccines: New Zealand's MeNZB vaccine initiative to control an epidemicDiana Lennon
Community Paediatrics, The University of Auckland, Auckland, New Zealand
J Paediatr Child Health 48:193-201. 2012....
- Once-daily amoxicillin versus twice-daily penicillin V in group A beta-haemolytic streptococcal pharyngitisD R Lennon
Department of Paediatrics, University of Auckland, Private Bag 92019, Auckland, New Zealand
Arch Dis Child 93:474-8. 2008..Rheumatic fever is a preventable chronic disease preceded by group A beta-haemolytic streptococcal (GABHS) pharyngitis...
- Meta-analysis of trials of streptococcal throat treatment programs to prevent rheumatic feverDiana Lennon
Community Paediatrics, University of Auckland, Auckland, New Zealand
Pediatr Infect Dis J 28:e259-64. 2009..Rheumatic fever (RF) is the commonest cause of pediatric heart disease globally. Penicillin for streptococcal pharyngitis prevents RF. Inequitable access to health care persists...
- Fast tracking the vaccine licensure process to control an epidemic of serogroup B meningococcal disease in New ZealandDiana Lennon
Community Paediatrics, School of Population Health, University of Auckland, Private Bag 92019, Auckland, New Zealand
Clin Infect Dis 49:597-605. 2009....
- School-based prevention of acute rheumatic fever: a group randomized trial in New ZealandDiana Lennon
Department of Paediatrics, University of Auckland, Auckland, New Zealand
Pediatr Infect Dis J 28:787-94. 2009..The efficacy of injectable penicillin, in high rheumatic fever incidence military environments is indisputable...
- Acute rheumatic fever in children: recognition and treatmentDiana Lennon
Department of Paediatrics, University of Auckland, Auckland, New Zealand
Paediatr Drugs 6:363-73. 2004..Primary prevention has been achieved innovatively in some countries, for example, Costa Rica, and more conventionally in some developed countries. Treatment of the acute episode controls symptoms and may limit cardiac damage...
- Guidelines for sore throat management in New ZealandMelissa Kerdemelidis
Community Paediatrics, School of Population Health, The University of Auckland, Auckland, New Zealand
N Z Med J 122:10-8. 2009..An algorithm and guideline for appropriate screening and management of sore throats in the New Zealand setting was crafted to guide appropriate treatment in high risk rheumatic fever areas and reduce antibiotic use in low risk areas...
- Immunogenicity, reactogenicity, and safety of a P1.7b,4 strain-specific serogroup B meningococcal vaccine given to preteensJamie Hosking
University of Auckland, Private Bag 92019, Auckland, New Zealand
Clin Vaccine Immunol 14:1393-9. 2007....
- Communicating information about sore throats and rheumatic fever to South Auckland high-school studentsN Harre
Department of Psychology, University of Auckland
N Z Med J 113:215-7. 2000..The present study examined the effectiveness of three modes of communication designed to increase high school students' knowledge about throat infections and rheumatic fever in a high risk area...
- Delayed immunisation and risk of pertussis in infants: unmatched case-control studyCameron C Grant
Department of Paediatrics, Faculty of Medicine and Health Sciences, University of Auckland, Private Bag 92019, Auckland, New Zealand
BMJ 326:852-3. 2003
- Proceedings of the Meningococcal Vaccine Strategy World Health Organization satellite meeting, 10 March 2004, Auckland, New ZealandKerry Sexton
University of Auckland, Auckland
N Z Med J 117:1 p preceding U1027. 2004..This will include real-time hospital-based monitoring in the regions first to roll out the vaccine...
- New zealand epidemic strain meningococcal B outer membrane vesicle vaccine in children aged 16-24 monthsSharon Wong
The University of Auckland, Auckland, New Zealand
Pediatr Infect Dis J 26:345-50. 2007..7b,4 since 1991. Children younger than 5 years are at highest risk. Previous serogroup B outer membrane vesicle (OMV) strain specific vaccines have shown variable efficacy in this age group...
- Safety and immunogenicity of New Zealand strain meningococcal serogroup B OMV vaccine in healthy adults: beginning of epidemic controlV Thornton
The University of Auckland, Meningococcal B Project, P O Box 98847, South Auckland Mail Centre, Auckland, New Zealand
Vaccine 24:1395-400. 2006..The safety and immunogenicity profile observed in this study of healthy adults enabled studies in children to be initiated using 25 microg dosage...
- Incidence, risk factors, and outcomes of Panton-Valentine leukocidin-positive methicillin-susceptible Staphylococcus aureus infections in Auckland, New ZealandS Muttaiyah
Department of Microbiology, Auckland City Hospital, Grafton, Auckland, New Zealand
J Clin Microbiol 48:3470-4. 2010..Those patients with PVL-positive MSSA infection were more likely to be of Pacific ethnicity, be younger in age, have community-onset infection, have SSTI, and need surgical intervention...
- Antibody persistence following MeNZB vaccination of adults and children and response to a fourth dose in toddlersCatherine Jackson
Epidemiology and Biostatistics, Community Paediatrics, School of Population Health Tamaki Campus, University of Auckland, Auckland, New Zealand
Arch Dis Child 96:744-51. 2011..A New Zealand serogroup B meningococcal epidemic prompted trials of a strain-specific (B:4:P1.7-2,4) outer membrane vesicle vaccine (MeNZB)...
- An Auckland regional audit of the nurse-led rheumatic fever secondary prophylaxis programmeSarah Grayson
Starship Hospital, Auckland District Health Board
N Z Med J 119:U2255. 2006..Rheumatic fever with ensuing rheumatic heart disease is considered to be a preventable chronic disease...
- Monoarthritis in rheumatic fever?Elizabeth Wilson
Pediatr Infect Dis J 26:369-70. 2007
- The New Zealand Meningococcal Vaccine Strategy: a tailor-made vaccine to combat a devastating epidemicKerry Sexton
Meningococcal Vaccine Strategy, Ministry of Health, Wellington, New Zealand
N Z Med J 117:U1015. 2004..A summary of the efficacy and safety data of existing outer membrane vesicle group B meningococcal vaccines is included as these data critically support the Strategy...
- Vaccine preventable diseases in indigenous populations - International perspectives. Satellite Symposium of the 5th International Symposium on Pneumococci and Pneumococcal Diseases, April 2006, Alice Springs, AustraliaRob Menzies
National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases, The Children s Hospital at Westmead, Locked Bag 4001, Westmead, New South Wales 2145, Australia
Vaccine 25:7281-4. 2007
- The strategy to control New Zealand's epidemic of group B meningococcal diseaseJane O'Hallahan
New Zealand Ministry of Health, Wellington, New Zealand
Pediatr Infect Dis J 23:S293-8. 2004..In New Zealand today, babies of Pacific ethnicity born in South Auckland have a 1-in-48 chance of contracting meningococcal disease by the time they are 5 years of age...
- MeNZB: a safe and highly immunogenic tailor-made vaccine against the New Zealand Neisseria meningitidis serogroup B disease epidemic strainPhilipp Oster
Chiron Vaccines, Siena, Italy
Vaccine 23:2191-6. 2005..In conclusion, these findings suggest that MeNZB is safe and is likely to confer protection against systemic group B meningococcal disease caused by the epidemic strain...
- From secondary prevention to primary prevention: a unique strategy that gives hope to a country ravaged by meningococcal diseaseJane O'Hallahan
Ministry of Health, Level 1, Old Bank Chambers, Customhouse Quay, P O Box 5013, Wellington, New Zealand
Vaccine 23:2197-201. 2005..Planning, co-ordinating and delivering the immunisation programme is a challenging project for the New Zealand Health Sector...
- Re: Immunogenicity and safety of a strain-specific MenB OMV vaccine delivered to under 5 year olds in New Zealand, Oster P, O'Hallahan J, Aaberge I, Tilman S, Ypma E, Martin D. Vaccine 2007;25(16):3075-9Diana Lennon
Vaccine 25:6835; author reply 6835-6. 2007
- Rheumatic fever diagnosis, management, and secondary prevention: a New Zealand guidelinePolly Atatoa-Carr
Waikato District Health Board, Hamilton
N Z Med J 121:59-69. 2008..This paper is a brief summary...
- The diagnosis and management of chronic rheumatic heart disease--an Australian guidelineWarren Walsh
Department of Cardiovascular Medicine, The Prince of Wales Hospital, Sydney, Australia
Heart Lung Circ 17:271-89. 2008
- The role of MeNZB vaccination in controlling the New Zealand meningococcal epidemicDiana Lennon
N Z Med J 121:110-2. 2008
- Re: "a prospective study of the effectiveness of the New Zealand meningococcal B vaccine"Diana Lennon
Am J Epidemiol 167:1140-1; author reply 1141-2. 2008
- Persistence of oral polio vaccine virus after its removal from the immunisation schedule in New ZealandQ Sue Huang
Institute of Environmental Science and Research, PO Box 50348, Porirua, New Zealand
Lancet 366:394-6. 2005..Sequence homology with Sabin vaccine parent strains indicated that polioviruses detected more than 4 months after the switch were of recent origin, consistent with importation from OPV-using countries...